hVIVO (LON:HVO) Shares Down 11.1% – Should You Sell?

hVIVO plc (LON:HVO)’s share price fell 11.1% during mid-day trading on Monday . The company traded as low as GBX 6.04 and last traded at GBX 6.04. 2,010,683 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 3,452,664 shares. The stock had previously closed at GBX 6.80.

Analyst Upgrades and Downgrades

HVO has been the subject of several research reports. Peel Hunt restated an “add” rating and issued a GBX 10 price objective on shares of hVIVO in a research report on Thursday, November 20th. Shore Capital lowered their price target on shares of hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of GBX 17.50.

hVIVO Stock Performance

The stock has a market capitalization of £41.53 million, a price-to-earnings ratio of 7.85 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock has a 50-day moving average of GBX 6.20 and a 200 day moving average of GBX 8.43.

Insider Buying and Selling

In other hVIVO news, insider Stephen Pinkerton bought 520,000 shares of the stock in a transaction on Monday, December 15th. The stock was purchased at an average price of GBX 6 per share, with a total value of £31,200. Also, insider Yamin Mo’ Khan bought 3,310,405 shares of the company’s stock in a transaction on Monday, December 15th. The shares were acquired at an average price of GBX 6 per share, with a total value of £198,624.30. Insiders own 4.43% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.